Carter and colleagues have recently demonstrated eradication of the CD34+ quiescent progenitor cells from BP-CML patient samples using the BCL2 inhibitor, venetoclax, in combination with TKIs (Carter et al., 2016). Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.